FMX-103 1.5%
Study FX2015-10
Phase 2 small_molecule completed
Quick answer
FMX-103 1.5% for Rosacea is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VYNE Therapeutics
- Indication
- Rosacea
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed